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pharmacogenetics in bipolar disorder
Naji C Salloum1,2, Michael J McCarthy1,2, Susan G Leckband1,2 and John R Kelsoe1,2,3*Abstract
Background: Bipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood
states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide.
Although effective treatments for BD exist, variability in outcomes leads to a large number of treatment failures,
typically followed by a trial and error process of medication switches that can take years. Pharmacogenetic testing
(PGT), by tailoring drug choice to an individual, may personalize and expedite treatment so as to identify more
rapidly medications well suited to individual BD patients.
Discussion: A number of associations have been made in BD between medication response phenotypes and
specific genetic markers. However, to date clinical adoption of PGT has been limited, often citing questions that
must be answered before it can be widely utilized. These include: What are the requirements of supporting
evidence? How large is a clinically relevant effect? What degree of specificity and sensitivity are required? Does a
given marker influence decision making and have clinical utility? In many cases, the answers to these questions
remain unknown, and ultimately, the question of whether PGT is valid and useful must be determined empirically.
Towards this aim, we have reviewed the literature and selected drug-genotype associations with the strongest
evidence for utility in BD.
Summary: Based upon these findings, we propose a preliminary panel for use in PGT, and a method by which the
results of a PGT panel can be integrated for clinical interpretation. Finally, we argue that based on the sufficiency of
accumulated evidence, PGT implementation studies are now warranted. We propose and discuss the design for a
randomized clinical trial to test the use of PGT in the treatment of BD.
Keywords: Bipolar Disorder, Pharmacogenomics, Lithium, Antidepressants, AntipsychoticsBackground
Bipolar disorder (BD) is a psychiatric illness that affects
3% to 5% of the population [1], and is characterized by
recurring and severe changes in mood, leading to sig-
nificant impairment, and increased risk for suicide.
The estimated direct and indirect costs of BD in the US
are estimated at $15B [2]. Mood stabilizers are considered
the treatment of choice for managing BD. However,
evidenced-based treatment guidelines include a wide
range of medications, such as antipsychotics, antidepres-
sants, anxiolytics and multi-drug combinations [3,4].* Correspondence: jkelsoe@ucsd.edu
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2014Despite the help of guidelines, psychiatrists face tremen-
dous challenges in treating BD. First, the presentation of
BD is heterogeneous, and the diagnosis of BD is often diffi-
cult. Psychiatric co-morbidity is common, and the typical
patient with BD is misdiagnosed an average of four times
[5]. After the diagnosis is established, treatment response is
often inadequate, and the rate of remission is poor, particu-
larly among those in the depressive phase [6]. Finally, many
drugs are poorly tolerated, and unwanted medication side
effects are common. Therefore, while there are broadly ac-
cepted best practices for treating BD, their application yields
variable, and often unacceptable, outcomes, leaving many
patients to suffer prolonged and unsuccessful drug trials be-
fore responding to treatment.
A challenge in treating BD is heterogeneity among pa-
tient responses. The same drug may have different out-
comes in two otherwise similar BD patients, successfullyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Box 1: Pharmacogenetic association studies versus
implementation studies
Genetic association studies have been used widely in psychiatric
pharmacogenetics to determine statistical associations between
genetic markers and a phenotype related to treatment
outcome, typically treatment response, or a major side effect
(for example, sexual dysfunction, Stevens-Johnson rash). These are
done either as candidate gene studies where a specific hypothesis
is tested or as GWAS in which associations sampled from across the
whole genome are examined independent of a specific hypothesis.
In association studies, patients are determined to be responder or
non-responder in categorical or quantitative terms, an assessment
that can be determined either prospectively or retrospectively. There
is typically no comparator treatment used in association studies.
bibuIn comparison, genetic implementation studies are relatively
rare in the psychiatry literature. These studies evaluate the
clinical utility of a genetic test(s) versus a control treatment that
does not utilize genetic information. Here, the association
between the genetic marker to the phenotype is assumed, and
the hypothesis tested is that the information provided by the
genetic marker will allow for better drug selection than would
occur in the absence of this information. Implementation
studies have to be prospective in order to determine the effects
of adding the information. The endpoints would be treatment
response and/or side effect burden at the end of the trial.
Salloum et al. BMC Medicine Page 2 of 152014, 12:90
http://www.biomedcentral.com/1741-7015/12/90treating one, but necessitating a search for an alternative
treatment in the other. For this reason, a typical course
of treatment is extensive, consisting of serial medication
trials until an effective drug or drug combination is identi-
fied. Variability in treatment responses may be related to
differences in illness pathophysiology and drug metabolism,
both factors thought to be influenced by an individual’s
genetic background. Therefore, understanding the relation-
ship between genetic factors and treatment response may
allow for the development of objective pharmacogenetic
tests (PGT) to guide the physician rationally and rapidly to-
wards effective drug treatments for BD.
Recently, many genetic variants have been associated
with response-related psychiatric phenotypes, including
many in BD. While the strength of this evidence varies,
some are now considered reliable. Despite this progress,
implementation of this knowledge in the clinic has been
limited. It remains unclear if association to response will
necessarily translate into improved outcomes, and there
has been a reluctance to apply these findings clinically.
Other medical disciplines have increasingly demonstrated
the utility of personalized medicine [7] with PGT showing
advantages in warfarin dosing [8], thiopurine myelosup-
pression in leukemia [9,10] and abacavir hypersensitivity
in HIV [11,12]. However, these fields are experiencing
similar inertia, even in cases where the supporting evi-
dence is strong [13].
Questions have been raised in the psychiatric literature
regarding the appropriateness of implementing PGT in
the clinic, most of which remain unanswered [14]. How-
ever, unlike genetic association studies which cannot ad-
dress clinical utility, implementation studies may provide
empirical answers to some of these pertinent issues [Box 1].
Hence, they are urgently needed. In this opinion, we con-
clude that a few PGT markers, while perhaps not perfect
are sufficiently well-established to advocate for research
into their implementation to determine if they have clinical
value. A preliminary path forward and discussion of the an-
ticipated benefits and obstacles is presented.
Discussion
Pharmacogenetic association studies
A large number of genetic markers have been associated
with psychotropic response in psychiatry, including many
relevant to BD. A number of reviews have been published
in recent years [14,15], focused primarily on lithium. How-
ever, many drugs used to treat major depression (MDD) or
schizophrenia (SCZ) are also effective in BD. Therefore, in
organizing this opinion around implementation, we have
broadened the scope of PGT in BD to consider these op-
tions in addition to lithium. PubMed and the PharmGKB
[16] database were searched for pharmacogenetic reports
for lithium, anti-seizure drugs, antipsychotics and antide-
pressants. We then devised criteria to rank these resultsbased on strength of evidence and clinical utility. In
doing so, we focused on variants that have been inde-
pendently replicated in large cohorts. In some cases, the
studies were performed in MDD or SCZ. We developed
standardized criteria by which genetic markers were
assessed. Those categorized as evidence Level 1 were
replicated at least once with a P-value of <0.05 after cor-
rection for multiple comparisons, in a total population
of ≥500 cases of similar ethnicity. Level 2 evidence required
replication with P-values <0.05 after correction and at least
one population of 100 to 499. Studies with P-values <0.05,
but without replication, or in samples <100 were catego-
rized as Level 3. Our search yielded a set of 16 genetic
markers that were classified as Level 1 (Table 1). We also
included a small number of variants that were compelling
candidates based upon convergent animal or pre-clinical
studies that met the threshold for Level 2 evidence. Each
genotype-drug association is discussed below.
Pharmacodynamics
Lithium response
Lithium is the most widely used mood stabilizer, greatly
decreasing suicide risk and BD symptoms during acute
mania, depression and maintenance [17,18]. Clinical
Table 1 Genetic variants with evidence supporting
clinical utility
Drug Gene Marker
Lithium BDNF rs6265
NTRK2 rs1387923
CREB1 rs6740584
GRIA2 rs9784453
GSK3B rs1954787
Carbamazepine HLA rs2844682; rs3909184
Antipsychotics DRD2 rs1799732
HTR2A rs6311
ANNK1 rs1800497
HTR2C rs3813929
SSRI’s GRIK4 rs1954787
HTR2A rs7997012
SLC6A4 5-HTTLPR
rs25531
Drug Metabolism CYP2D6 Multiple markers [124-126]
CYP2C19 Multiple markers [115,151-153]
SSRI’s, selective serotonin receptor inhibitors.
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[19,20], leading some to argue that lithium responsive
BD is a distinct illness subtype that can be defined in
part by its sensitivity to the drug [21]. However, in a long
term prospective study [22], while lithium response
was identified as an enduring trait, the classical clinical
profile failed to discriminate lithium responders from
non-responders. For this reason, efforts have been directed
towards pharmacogenetic approaches predicting lithium re-
sponse. Table 2 summarizes some of the genetic markers
reported to be associated to mood stabilizer response.
BDNF and NTRK2
Brain-derived neurotrophic factor (BDNF), plays a crucial
role in neuronal survival, differentiation and plasticity
in the brain [23-25]. BDNF binds to the TrkB receptor,
the protein product of NTRK2. The BDNF/TrkB signal-
ing pathway is involved in a wide range of intracellularTable 2 Genetic markers associated with mood stabilizer outc
Drug/Phenotype Gene Marker Subjects Studies Diagnos
Lithium BDNF rs6265 538 3 BD I/II
NTRK2 rs1387923 284 1 BDI
CREB1 rs6740584 258 1 BD I/II
GRIA2 rs9784453 817 2 BD I/II
ODZ4 rs11237637 817 2 BD I/II
GSK3B rs1954787 307 3 BD I
Carbamazepine HLA HLA-B*1502 380 2 Unspecif
BD, bipolar disorder; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolyssignaling cascades [26] and is thought to play an important
role in mediating the therapeutic effects of lithium [27,28].
Past evidence has implicated BDNF in the pathogenesis of
BD [29-31], and the BDNFVal66Met polymorphism (rs6265)
has been associated with lithium response, whereby carriers
of the Met allele had better treatment outcomes [32,33].
The lithium response association with BDNF was recently
replicated in a sample of Chinese patients with BD [34], but
others have failed to replicate the result [35]. NTRK2 poly-
morphisms have been implicated as genetic factors under-
lying BD in a genomewide association study (GWAS) [36]
and associated with lithium response in two independent
studies. In the first, two SNPs in NTRK2 were associated
with response specifically in patients with euphoric mania
[37]. This association has been subsequently replicated in
an independent prospective trial [38]. More recently, an-
other independent study again implicated NTRK2, using a
different variant [39]. However, not all studies have repli-
cated the NTRK2 association with lithium response [32].
Different variants in NTRK2 have been associated with risk
for suicide attempts, which is particularly interesting in the
light of lithium’s known anti-suicide properties [40].
CREB
The cAMP response element-binding protein (CREB1) is a
transcription factor that plays important roles in neuroplas-
ticity, cell survival and neuronal modulation by lithium and
antidepressants [41-43]. An association between variants in
CREB1 and lithium response was reported in a prospective
association study conducted on a sample of 258 subjects
followed over three years, in which the BD subjects were
treated with lithium monotherapy [44]. Of interest, inde-
pendent CREB1 haplotypes have been associated with se-
lective serotonin receptor inhibitor (SSRI) remission [45],
emergent suicidal ideation during SSRI treatment [46] and
treatment resistant depression [47], features previously
linked to latent bipolarity among depressed subjects.
GRIA2, ODZ4/TENM4
In a GWAS of lithium response conducted using subjects
from the Systematic Treatment Enhancement Program for
Bipolar Disorder (STEP-BD), five SNPs showed associationomes
is Phenotype association Level of evidence
A(Met)-allele associated with better response 1
T-allele associated with better response 2
GA genotype associated with better response 2
A-allele associated with worse response 1
T-allele associated with worse response 1
C-allele associated with better response 2
ied HLA-B*1502 associated with SJS/TEN 2
is.
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licated in a cohort of 359 BD patients. Among these
was a variant in GRIA2, a glutamate receptor subunit
gene [48]. Glutamate has been strongly implicated in
the pathogenesis of BD, and GRIA2 was previously
shown to be regulated by lithium in hippocampal neu-
rons [49]. ODZ4 (also named TENM4), has been asso-
ciated with BD susceptibility in the largest published
GWAS to date and was also found to be associated
with lithium response [50,51].
GSK3B
Glycogen synthase kinase 3β (GSK3B), is an enzyme in-
volved in neuronal development and survival, and is inhib-
ited by lithium [52,53]. A pharmacogenetic study of 88 BD
patients identified a functional SNP associated with lithium
response in the GSK3B promoter [54]. Similar results were
obtained in a cohort of 138 Taiwanese BD subjects [55] and
a mixed cohort of BD/MDD receiving augmentation of an-
tidepressants with lithium [56]. However, other studies have
failed to detect a similar association [57,58].
Carbamazepine response
The anticonvulsant carbamazepine (CBZ) is a mainstay
of treatment in BD patients [59,60]; however, no phar-
macogenetic studies to date have evaluated response to
carbamazepine. Clinical features associated with CBZ re-
sponse include those with BPII disorder, dysphoric mania,
comorbid substance abuse, mood incongruent delusions,
negative family history of BD in first-degree relatives, and
in those not tolerant to other treatments due to side ef-
fects (for example, weight gain, tremor, diabetes insipidus,
or polycystic ovarian syndrome) [61].
There has been a strong association reported between
the HLA-B*1502 haplotype and the severe life-threatening
cutaneous drug reactions, Stevens-Johnson syndrome (SJS)
and toxic epidermal necrolysis (TEN) [62]. Two studies
conducted on Han Chinese patients reported that HLA-
B*1502 was present in 100% (44/44) and 98.3% (59/60) of
CBZ-induced SJS patients in contrast to 3% (3/101) and
4.2% (6/144) of CBZ-tolerant patients [63,64]. While the
risk-associated haplotype is found in 5% to 15% of Asians,
clinical guidelines in some healthcare institutions suggest
avoiding carbamazepine in all patients of Asian background,
thereby potentially depriving the majority of patients in this
racial group a proven treatment for BD. Hence, the adapta-
tion of PGT for HLA-B has a huge potential for impact in
this group and HLA-B PGT for carbamazepine treatment
is now recommended by the Clinical Pharmacogenetics
Implementation Consortium (CPIC) [65].
Valproic acid response
Relatively little work has been done on the pharmacogenetic
response to the anticonvulsant mood stabilizer, valproicacid, and no valproic acid study meets the requirements
for inclusion in our implementation list. However, valproic
acid is a first line treatment for BD, and its omission con-
stitutes an important gap. Valproic acid pharmacogenetics
is likely to be a priority for future research.
Antipsychotic response
Antipsychotics are commonly used in BD, both as a
first-line treatment in acute mania [66] and depression
[67]. However, psychiatrists are increasingly reluctant
to use them due to their unfavorable long-term side effect
profile, especially weight gain [68]. In addition to metabolic
problems, the risk of extra-pyramidal side effects (EPS) as-
sociated with second generation antipsychotics is estimated
to be 13% to 17% and remains a concern.
Because the majority of the pharmacogenetic studies
of antipsychotics have been done with SCZ patients, it
requires extrapolation to BD. For this reason, caution is
required in interpreting these results. However, many of
these data likely apply to BD. First, there is substantial
symptom overlap and shared genetic risk between SCZ and
BD [50,69], suggesting that underlying illness mecha-
nisms are shared. Moreover, because side effects such
as weight gain are assumed to be due to ‘off target’ ef-
fects, side effect mechanisms are likely similar across
disorders. To be sure, research extending PGT of anti-
psychotics to BD is required, not only with regard to
psychotic symptoms, but also with respect to mood.
Genetic variants reported to be associated with anti-
psychotic response are listed in Table 3.
DRD2/ANKK1
The D2 dopamine receptor encoded from DRD2 is the
primary target of most antipsychotic medications [70,71].
The -141C insertion/deletion polymorphism located in the
DRD2 promoter, has been shown to have a functional effect
on expression and has been studied on several occasions
with respect to antipsychotic outcomes. In a meta-analysis
of 687 SCZ patients from six studies, the -141C variant
demonstrated an association with favorable antipsychotic
response (>50% reduction in symptoms) at eight weeks
[72]. The ankyrin repeat and kinase domain containing 1
gene (ANKK1) is located 10 kb from DRD2 [73], and
has been associated with tardive dyskinesia (TD). In a
meta-analysis of 1,256 SCZ subjects from six studies,
ANKK1 genotype was associated with TD, with odds ratios
of 1.30 to 1.50 [74]. A decrease in DRD2 expression was
also associated with a risk conferring allele [75,76], perhaps
explaining the effect of ANKK1 genotype on TD risk [77].
HTR2A
Many antipsychotic drugs alter serotonin signaling by
blocking 5HT2A receptors, encoded by HTR2A [78].
Several studies demonstrated a less favorable response
Table 3 Genetic markers associated with antipsychotics outcomes
Drug/Phenotype Gene Marker Subjects Studies Diagnosis Phenotypic association Level of evidence
Antipsychotics DRD2 rs1799732 687 6a Schizophrenia Del-allele associated with poor response 1
HTR2A rs6311 315 2 Schizophrenia A-allele associated with good response 2
ANNK1 rs1800497 1,256 6a Schizophrenia A2-allele associated with TD risk 1
HTR2C rs3813929 1,108 14a Schizophrenia C-allele associated with weight gain 1
MC4R rs489693 344 4 Unspecified AA genotype associated with weight gain 2
rs17782313 345 1 Multiple C-allele associated with weight gain 2
aIncludes meta-analyses. TD, tardive dyskinesia.
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functional promoter variant, A-1438G in HTR2A [79-81].
HTR2C
In attempts to identify genetic vulnerability to antipsychotic
induced weight gain and metabolic syndrome, HTR2C,
encoding the 5-HT2C receptor, has yielded the most
reliable associations. A meta-analysis of eight studies
showed a significant association of C759T HTR2C SNP,
with a lower risk of weight gain with antipsychotics [82].
Similarly, ten independent studies on schizophrenic patients
have shown a significant association between the C-allele of
the same SNP and higher risk of antipsychotic-induced
weight gain [77].
MC4R
MC4R, one of the most important genes associated with
weight gain and increased risk for obesity [83,84], has been
shown to play a role in the modulation of food intake and
energy homeostasis [85,86]. It has also been associated with
atypical antipsychotics-induced weight gain in a GWAS
conducted on 139 pediatric subjects, with replication in
three additional cohorts [87]. Another SNP, previously as-
sociated with weight gain [83] yielded similar results [88].
Antidepressant response
Although controversial [89], SSRIs are widely used in
conjunction with mood stabilizers or antipsychotics for
depression in BD, appearing in evidence-based psycho-
pharmacology guidelines [90,91]. However, because of
their questionable efficacy and potential for inducing
mania, there is a need to identify genetic variants associated
with response and adverse events, such as manic switch
and rapid cycling. SSRI response has been primarily studied
in MDD or mixed BD/MDD samples. Therefore, our ex-
trapolation from MDD to BD may have important ca-
veats in the use of these markers. Table 4 summarizes
genes associated with antidepressant response.
SLC6A4 (5-HTTLPR)
The 5-HTTLPR is a 44 bp insertion/deletion within the
promoter of SLC6A4, the gene encoding the serotonin
transporter [92]. Transcriptional activity among carriers ofthe short allele (S) has been shown to be lower compared
to carriers of the long allele (L) [92,93]. Fifteen studies
encompassing 1,435 MDD and BD patients were analyzed
for association with SSRI response [94]. The L variant was
associated with a better response, while SS genotype was
linked to lower rates of remission and longer response
times. BD patients carrying the S allele were also more
susceptible to developing anti-depressant-induced mania
(AIM) with a 35% increase in risk [95].
GRIK4
The Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) study included an initial period of
citalopram monotherapy. Of these SSRI-treated subjects,
1,816 were genotyped in a candidate gene study of 768
SNPs, identifying an association between the GRIK4 SNP
rs1954787 and therapeutic response [96]. GRIK4 is a
component of the ionotropic kainate/glutamate receptor.
An attempt to replicate this finding in 387 BD/MDD
subjects found supportive evidence for a GRIK4 associ-
ation, but not at the same SNP, and required a gene x gene
interaction [97].
HTR2A
Since the serotonin transporter is a direct target of SSRIs,
modulation of serotonin transmission has long been
thought a key mechanism of action. A number of serotonin
receptors have been studied and, in the STAR*D sample, an
analysis of 1,953 patients revealed a strong association be-
tween the intronic HTR2A SNP rs7997012 and treatment
response [98]. In a synergistic manner, homozygous carriers
of the protective alleles of both GRIK4 and HTR2A were
23% more likely to respond to citalopram than participants
carrying neither of these alleles [96].
FKBP5
FKBP5 has been implicated in psychiatric disorders be-
cause of its role encoding a co-chaperone protein for
the glucocorticoid receptor. It has been shown to affect
the hypothalamic–pituitary–adrenal (HPA) [99,100] and
modulate Akt activity [101], thereby altering numerous
neuronal functions [102,103]. Variation in FKBP5 was first
associated with antidepressant response in two independent
Table 4 Genetic markers associated with antidepressant response
Drug/Phenotype Gene Marker Subjects Studies Diagnosis Phenotype association Level of
evidence
Antidepressant GRIK4 rs1954787 1,816 2 MDD CC genotype associated with better citalopram response 1
HTR2A rs7997012 1,329 1 MDD A-allele associated with better citalopram response 1
SLC6A4 5-HTTLPR 1,435 15 MDD, BD long allele associated with better SSRI response,
short allele increases risk of AIM
1
FKBP5 rs4713916 1,426 4 MDD, BD,
dysthymia
A-allele associated with better antidepressant response 1
ABCB1 rs2032583,
rs2235040
689 2 MDD C and A alleles respectively associated with better response 1
424 1 MDD C and A alleles respectively associated with adverse effects 2
AIM, antidepressant induced mania; BD, bipolar disorder; MDD, major depression; SSRI, selective serotonin receptor inhibitor.
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studies including more than 2,199 patients, this associ-
ation was replicated [105].
Genome-wide association studies
Because the results have been better replicated, most of
the markers discussed above come from candidate gene
studies. However, by surveying the entire genome, GWAS
have the ability to identify previously unrecognized phar-
macogenetic markers that could not be predicted based on
candidate hypotheses. While some of these studies require
replication or have failed to achieve genome-wide signifi-
cance, several large GWAS of drug response have been
conducted and are worthy of mention.
A GWAS of lithium response recently reported very
strong evidence of association (P = 10−37) for a variant in
the gene glutamic acid decarboxylase like 1 (GADL1) in
a sample of 294 Taiwanese subjects [106]. This result was
then replicated in smaller samples of 100 and 24 subjects
by the same investigators. This is an exciting result await-
ing independent replication. A GWAS analysis of citalo-
pram response in the STAR*D cohort yielded suggestive
associations for markers in RORA, UBE3C and BMP7, but
none that met genome wide thresholds for significance
[107]. A similar analysis revealed a number of suggestive
associations of citalopram-induced side effects, most
prominently a marker in EMID2, associated with altered
vision and hearing [108]. More recently, data emerged
from a meta-analysis of >2,200 MDD patients from the
STAR*D, Genome-Based Therapeutic Drugs for Depression
(GENDP) and Munich Antidepressant Response Signature
(MARS) trials [109]. In this study, a number of suggestive
markers were associated with various response indicators,
but none met genome-wide thresholds for significance.
Taking a different approach, GWAS analysis for copy num-
ber variation using the STAR*D sample and a health system
repository revealed a modest enrichment of chromosomal
duplications among treatment refractory depression cases,
and a deletion in PABPC4L uniquely affecting treatment re-
sistant MDD patients, but was restricted to only a small
number of subjects [110].As with case–control studies of BD, MDD and SCZ,
GWAS approaches have generally not supported previously
reported candidate gene associations. While the reasons for
this discrepancy are unclear, it does underscore the rela-
tive strengths and weaknesses of candidate gene studies
and GWAS. Candidate gene studies are limited in scope,
focusing on individual genes, while GWAS surveys the
entire genome. Yet because of this focus, candidate gene
studies often have greater statistical power with smaller
sample sizes for any individual gene. Practically, however,
these studies do not generally correct for the total number
of SNPs examined in the same sample. The price of the
wide scope of GWAS is the large number of statistical
tests and the very large sample sizes required to achieve
statistical significance. Such large sample sizes are particu-
larly problematic for pharmacogenetics where the cost of
assessing the phenotype, via a prospective clinical trial, is
very high, and uniformity of treatment among subjects is
rare. Future GWAS with larger samples will likely identify
many new drug response loci. Until then, we argue that
the strongest candidate gene markers likely provide valid,
but incomplete, answers that warrant testing for utility.
Pharmacokinetics
CYP450 enzymes
Cytochrome P450 enzymes constitute a major compo-
nent of the human drug metabolism system, activating/
deactivating and facilitating the elimination of compounds
[111,112]. Many drugs used to treat BD are eliminated by
CYP450 enzymes, and knowledge of a patient’s CYP450
genotype can be invaluable in selecting medications or
doses. While pharmacokinetics have been largely neglected
in previous reviews of the pharmacogenetics of BD, CYP450
genotyping is now approaching mainstream use, with FDA
approval of CYP450 testing for 27 alleles in CYP2D6
and three alleles in CYP2C19 [113,114]. CYP450 geno-
types are highly variable, with numerous functionally
distinct haplotypes, but are frequently organized by
metabolic activity into different phenotypic categories. For
example, 2D6 phenotypes are commonly classified as:
poor metabolizers (PM) with completely absent enzymatic
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enzymatic activity; extensive metabolizers (EM) with nor-
mal enzymatic activity; and ultra-rapid metabolizers (UM)
with increased enzymatic activity [115]. The relative fre-
quency of minor allelic variants differs greatly by ethnicity
[116-118]. For example, among East Asians approximately
30% carry the null CYP2C19 haplotypes *2 and *3, that
lead to a total absence of CYP2C19 activity. In contrast, the
frequency in Caucasians ranges from 4% to 13% [119]. On
the other hand, <5% of East Asians possesses the CYP2C19
*17 allele that increases activity, whereas the rate in
Northern European Caucasians is 18% [120,121].
CYP2D6
CYP2D6 is involved in the metabolism of more than 70
drugs, including many anti-depressants and anti-psychotics.
The CYP2D6 gene is located at 22q13.1, and encodes the
CYP2D6 enzyme [122,123].
CYP2D6 and antidepressants
CYP2D6 genotype has been shown to be associated
with antidepressant outcomes across several dimensions
[124-126]. Response to venlafaxine was significantly greater
in CYP2D6 EM subjects who metabolize the drug nor-
mally compared IM subjects who require lower doses
[127]. MDD patients showed higher rates of remission
among CYP2D6 IMs compared to PMs, after eight weeks
of escitalopram treatment [128]. CYP2D6 UM status con-
tributed to non-response by increasing early dropout rates
[129,130], and CYP2D6 UM status was associated with a
higher risk of suicide [131-133]. Finally, CYP2D6 genotype
predicts the risk of adverse effects as shown among PMs
treated with venlafaxine and tricyclic antidepressants
(TCAs) [134,135]. Most dramatically, cases have been
reported of PMs being linked to fatal responses to anti-
depressants [136,137]. While compelling evidence links
functional CYP2D6 haplotypes to drug levels [138], other
studies failed to determine an association between CYP2D6
polymorphisms and treatment response [139-141], leading
the Evaluation of Genomic Applications in Practice and
Prevention (EGAPP) group to conclude that the evidence
in support of CYP2D6 genotyping for guiding antidepres-
sant treatment is inconclusive, and recommending imple-
mentation clinical trials in order to show the benefits from
CYP450 genotyping [142].
CYP2D6 and antipsychotics
CYP2D6 mediates the metabolism of many antipsychotics,
making the use of genetic information about this locus a ra-
tional strategy for personalized medicine [143-146]. How-
ever the utility of CYP2D6 genotyping in predicting clinical
response to antipsychotics is relatively unexplored. CYP2D6
genotype did predict tolerability to risperidone with a
higher risk of adverse effects among PMs [147,148].CYP2C19
CYP2C19 is involved in the metabolism of a wide range
of anti-depressants and benzodiazepines [149,150]. The
CYP2C19 gene is located at 10q24.1-q24.3.
CYP2C19 and antidepressants
CYP2C19 has been shown to be the primary metabolic
enzyme for citalopram, escitalopram, amitriptyline and
clomipramine [115,151-153]. Functional CYP2C19 haplo-
types have been associated with serum concentrations of
citalopram [151,154] and escitalopram [138,155]. Analysis
of the Caucasian subset of the STAR*D sample revealed
an association between the inactive *2 allele and tolerance
to citalopram [156].
Other pharmacokinetic targets
ABCB1
P-glycoprotein (P-gp), one of the ATP-binding cassette
(ABC) transporter proteins, actively transports drugs,
including antidepressants, across the blood–brain barrier
[157,158]. Multiple SNPs in ABCB1, coding for P-gp, were
associated with response to citalopram, paroxetine, amitrip-
tyline and venlafaxine, substrates of P-gp [159]. Two of the
latter were replicated in a geriatric sample receiving paroxe-
tine [160] and associated with SSRI-related adverse effects
in a separate study [161].
Pharmacogenetics and clinical practice: are we there yet?
Psychiatry lacks objective biological disease markers
to guide diagnosis and treatment, creating a situation
analogous to cardiologists relying on subjective descrip-
tions of chest pain, without the aid of electrocardio-
grams, biochemical markers, or blood pressure cuffs to
differentiate among syndromes or track recovery. While
the discovery of predictive genetic markers is just be-
ginning, evidence already exists for a number of well
replicated PGT markers. This has raised a number of
questions in the psychiatric literature [162], including:
How strong must the supporting evidence be? How
large is a clinically relevant effect? What degree of
specificity and sensitivity are required? Does a given
marker influence decision making and have clinical
utility? In short, can the existing genetic data be trans-
lated from statistical associations to clinically inform-
ative tools? The answer remains unclear. A genetic
marker can correlate with an outcome, but be deemed
clinically useless because of low predictive value, poor
specificity or limited external validity [163,164]. Some
have argued against implementation [162-165], conclud-
ing that PGT markers are not yet sufficiently sensitive
or specific [165]. However, the utility or lack of utility
of PGT is an empirical question that has remained
largely untested.
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The gold standard for determining the utility of a
therapeutic intervention is the randomized clinical
trial. This method is readily applied to PGT by com-
paring the outcomes of PGT guided treatment against
treatment as usual (TAU). Figure 1 illustrates a simple,
two arm design that could test the clinical utility of
PGT. Outcomes could be measured across a number of
dimensions including response magnitude, time to re-
sponse, symptom burden, side effect burden, disability
and cost. In principle, improvement on even a single
dimension could constitute a successful trial.
Designing the test panel
The design of PGT panels is likely to evolve rapidly.
Costs for whole genome sequencing are falling rapidly,
and it is expected that this technology will be widely
available once the cost drops below $1,000 [166].
Therefore, in the near future, costs of whole genome
sequencing will be comparable to other common med-
ical tests, allowing for the patient’s entire genetic se-
quence and interpretation to be part of the electronic
medical record. In the interim, candidate gene panels
composed of a limited set of markers, targeting key
biological functions offer a cost effective and technic-
ally plausible format for focused genotyping. For illus-
trative purposes, we have selected the well replicated
markers described above to show how a candidate
gene variant panel might be selected, configured and
implemented.Figure 1 A pharmacogenetics implementation design. Patients are ran
treatment as usual (TAU). For the PGT group, the physician incorporates th
the physician treats according to usual practice based on evidence-based t
compared after the specified treatment interval.Reporting and recording genetic results
Most psychiatrists lack training in advanced genetics and
may have difficulty understanding PGT results. Therefore,
in the design of a PGT, it is important to convey results in
a simple manner that can be understood and quickly in-
corporated into clinical decision making without losing
pertinent detail. To address the dilemma presented by
these competing interests, a PGT report may require mul-
tiple layers, each coherent and internally consistent, that
presents information with increasing levels of detail, start-
ing with general drug recommendations and ending with
the raw genotype results and technical details of the assay.
An algorithm for integrating genetic results
Frequently, a medication may have multiple, relevant
genetic marker associations (for example, one for response,
others for side effects), a genetic marker may be relevant
to multiple medications, and different genetic markers may
suggest opposite actions. Therefore, the PGT results
for each variant need to be reconciled and consolidated
into a single, overall recommendation. The process of
synthesizing PGT results from multiple markers into co-
herent treatment recommendations for the physician may
prove challenging. One solution to this challenge is to de-
velop algorithms that prioritize and apply differential weight
to potential clinical outcomes (Figure 2). We approached
this by first classifying all relevant drug-marker combi-
nations into four clinical recommendations: 1) use
with caution; 2) potential limitations to use; 3) use as
directed; and 4) preferred use. We then developed an algo-
rithm (Figure 2), that generates an overall recommendationdomized to pharmacogenetic test (PGT) guided treatment or
e results of the test to make treatment decisions; in the TAU group,
reatment guidelines. Subjects are assessed longitudinally and outcome
Figure 2 Integrating pharmacogenetic test results. An algorithm for translating genotypes into specific recommendations for drugs
commonly used in BD is illustrated. In making an overall treatment recommendation, all possible drug-genotype combinations are classified into
four outcome categories. The overall recommendation is optimized to avoid the worst outcome predicted by PGT. Drug-genotype combinations
associated with serious and/or potentially life threatening outcomes are given lowest priority (Use with caution). Drug-genotype combinations
with an elevated risk of long term side effects or that are predicted to require higher dosing requirements are given the next lowest priority
(Potential limitations to use). Drug-genotype combinations that are not associated with an increase in adverse events are recommended for use
in accordance with standard practices (Use as directed), and those without an elevated risk for adverse events, and an association with good
psychiatric outcomes are given highest priority (Preferential use). EM, extensive metabolizer; IM, intermediate metabolizer; NA, not available; PM,
poor metabolizer; TD, tardive dyskinesia; UM, ultra-rapid metabolizer; UNKN: unknown.
Salloum et al. BMC Medicine Page 9 of 152014, 12:90
http://www.biomedcentral.com/1741-7015/12/90for each drug based on genotype. In this algorithm, drugs
are serially considered in descending order of expected
adverse events, starting with the most severe. For example,
genotypes that predict high risk for life-threatening/
serious adverse effects are considered first, thereby re-
moving drugs that could present imminent danger to
the subject (for example, HLA-B1502 and SJS). Medica-
tions are then considered with respect to genetic risk of
long-term side effects and/or higher dosing requirements
(for example, CYP450 UMs). Finally, drugs are assessed interms of genetic associations with symptom response.
The set of drugs with minimal side effect associations,
but no information on response will be classified for
‘Use as directed’. Those with minimal/no side effect
associations predicted to show a good response are
classified for ‘Preferred use’. Given the common nature
of many of the risk-associated markers that preclude
‘preferred’ status, this latter set of drugs will typically
be small, (perhaps even nonexistent for patients with
some genotypes), but optimally matched to an individual,
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decision’, and eliminating choices that are less likely to
work or to be poorly tolerated. Importantly, the algorithm
does not replace clinical judgment, and the physician is free
to incorporate relevant information from other sources
(for example, clinical features, drug-drug interactions)
to weigh options alternatively, or, when indicated, to
override the algorithm.
Special considerations in clinical trial design
There are several factors that differ between a PGT
implementation study and a randomized clinical trial
(for example, for a medication) or genetic association
study that warrant special consideration. First, in design-
ing an implementation study, a panel of genetic markers is
evaluated, not a single genetic marker, and the efficacy of
the panel as a whole is tested. Not all markers will be rele-
vant to a given patient or decision, but the breadth of
multi-marker panels affords the clinician an opportunity
to survey several low frequency alleles with good effi-
ciency, offering broad utility in a naturalistic environment.
This approach does have limited ability to test the benefit
of any single genetic association included in the panel. It
is assumed that not every result will support a previously
established genetic association, but that in aggregate, treat-
ment outcomes will be improved based on the PGT results.
Over time, data can be collected regarding clinician choices
and specific markers. In this manner, insight into which
components of the test are most useful can be developed.
In an implementation study, the effectiveness of treat-
ment, regardless of the specific drug(s) used is the most
important variable. The hypothesis is that outcomes in
PGT are superior to TAU as a result of genetic information
being conveyed to the physician, not that a specific drug
is better. Appropriate clinical use of PGT data will differ
among clinicians, and this variability must be controlled.
The use of evidence-supported clinical treatment guide-
lines can standardize some practices. However, ‘real world
patients’, particularly those with treatment refractory
symptoms, often have extensive treatment histories that
can make it difficult to fit them into standardized algo-
rithms. To mitigate this difficulty, experimental blinding is
essential. Since the physician is required to interpret genetic
data and make decisions based upon the results, the phys-
ician cannot be blinded. However, by obtaining DNA on all
subjects, patients can be blinded if their data are withheld.
Independent raters can also be blinded to assess out-
comes. Many other clinical trial designs are possible,
and their respective strengths and weaknesses have
been recently reviewed [162].
Early implementation studies
Using a panel of five genetic markers and a design similar
to the one outlined above, a PGT implementation study of44 MDD patients was completed using a commercially
available test, yielding promising results [167]. Treatment
refractory patients with MDD were divided into PGT
and TAU groups. Depressive symptoms were significantly
decreased in the PGT group compared to TAU, as shown
by greater reductions in QIDS-C16 and HAM-D17 scores
at the eighth week. More recently, similar differences were
shown by the same group using a larger replication sample
of 227 MDD patients [168]. The same test was retrospect-
ively applied to 97 subjects for whom health insurance re-
cords were available. In this way, genetic testing predicted
healthcare utilization and costs. When patients were pre-
scribed medications later found to be poorly matched to
genotype, they required more frequent visits, took more
medication and required greater expenditures [169]. In all
three of these reports, differences in outcome were driven
primarily by the genotypes expected to have the most se-
vere outcomes, primarily those expected to metabolize
medications poorly, resulting in more adverse effects.
Strikingly, these most severe mismatches were commonly
encountered, affecting approximately 25% of the subjects
in one study [168]. Several limitations in these studies
warrant mention. First, both efficacy trials were open label
and not randomized, meaning that patients were aware of
their group assignment. Second, the samples were small,
ethnically homogenous and collected from single sites, po-
tentially limiting the external validity of the results. None-
theless, the improvement over TAU is particularly striking
given the nature of the subjects, many of whom suffered
from chronic refractory depression. To date, no trials in BD
have been conducted.
Summary
Statistically significant, but clinically significant?
The findings summarized indicate that a number of
PGT markers are reliably associated with clinically sali-
ent treatment outcomes. Although this is a very early
stage in the discovery of PGT markers in BD, this set of
genes is expected to be refined and enlarged over time,
and we argue that there are already enough potentially
informative results to warrant implementation studies to
determine their clinical utility.
Whether or not the pharmacogenetic panel presented
here can be used to improve outcomes in clinical practice
is an untested question. In clinical trials, the concepts of
effect size, sensitivity (labeling a true positive as positive)
and specificity (labeling a true negative as negative) are
used to measure the value of a biological test. Psychiatric
PGT has been criticized for individual allelic associations
falling short on these measures. However, three counter-
points can be offered. First, PGT implementation takes ad-
vantage of multiple genetic markers, and while individual
markers may be non-specific, limited in applicability, or
yield small effects, a more comprehensive panel, utilizing
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the absence of objective markers to guide decisions, medi-
cation choice in BD is presently made in a largely trial and
error fashion. In this case, even small improvements in
care could represent a significant advance. Third, the inter-
actions among genetic variants, medications and individual
patients are sufficiently complex that a priori estimates of
sensitivity and specificity may not accurately predict the
outcome of a PGT trial. Only empirical data can determine
the value of PGTs in clinical practice. Hence, we conclude
that the potential for benefit from PGT is high, and will
only increase as whole genome sequence information
becomes widely incorporated into newer PGT panels and
new genetic associations are discovered.
On the other side of the equation, the costs of repeated
medication trials, prolonged illness, clinician time and un-
anticipated adverse drug events are also high, while the
cost of genotyping, incurred only once, is relatively low,
and likely to drop further. Therefore, while the potential
for therapeutic gains may be modest in the first iterations
of PGT, the downside risk imposed upon the patient is
minimal, making the cost-benefit ratio strongly favorable.
Therefore, carefully designed implementation studies
constitute an essential and effective tool in addressing
these concerns while playing an instrumental role in
the validation process of genetic tests and their intro-
duction into routine psychiatry practice. Implementa-
tion studies, as proposed here, will likely be a useful
approach in deciding the value of a genetic test in real
world clinical situations [162].Abbreviations
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